MedTrace Logo

Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial

NCT05089344 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2021-10-22

No results posted yet for this study

Summary

This study is done aiming to Assess Efficiency of Growth hormone as an adjuvant in pretreatment of Poseidon type IV group " poor responders "undergoing ICSI using minimal induction protocol

Conditions

  • Poor Response to Ovulation Induction Poseidon Type IV

Interventions

DRUG

Growth Hormone

growth hormone

DRUG

Clomiphene citrate daily and recombinant FSH (Gonal-F®)

Clomiphene citrate daily and recombinant FSH (Gonal-F®)

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Principal Investigators

  • Moustafa Fouad, MD · Ainshams Maternity Hospital

  • Ebtihal ElTaieb, MD · Ainshams Maternity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-09
Primary Completion
2022-10-30
Completion
2022-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089344 on ClinicalTrials.gov